Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

EMD Serono / Merck KGaA: Clinical Trials & FDA Approval Profile

EMD Serono / Merck KGaA (Darmstadt, DE / Rockland, MA) sponsors 46 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (6 recruiting now), 18 completed protocols, and 19 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)32.6%
Median Closed Enrollment vs National (145 pts)140 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for EMD Serono / Merck KGaA
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)46
Active Pipeline (Recruiting Now)13 (6)
Completed vs Stopped Early18 / 15 (32.6%)
Median Closed Actual Enrollment140 participants
Physical Hospital Site Disclosure83.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals19 (2 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With EMD Serono / Merck KGaA
Hospital Research SiteLocationShared Protocols
Asan Medical CenterSeoul14
Seoul National University HospitalSeoul12
Samsung Medical CenterSeoul, Gangnam-Gu11

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by EMD Serono / Merck KGaA
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07549412A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With PrevPhase IIIRECRUITING
NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)Phase IIIRECRUITING
NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyCladPhase IIIRECRUITING
NCT07332481A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseasePhase IIIRECRUITING
NCT05327530A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the EMD Serono / Merck KGaA Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI